Literature DB >> 3261652

Surgical survival benefits for coronary disease patients with left ventricular dysfunction.

E P Bounous1, D B Mark, B G Pollock, M A Hlatky, F E Harrell, K L Lee, J S Rankin, A S Wechsler, D B Pryor, R M Califf.   

Abstract

Controversy still exists about the proper selection of patients with coronary artery disease and left ventricular dysfunction for coronary bypass surgery. To examine this issue, we studied 710 patients with significant coronary artery disease and left ventricular dysfunction (ejection fraction less than or equal to 40%). Of 301 patients treated surgically, 232 had bypass grafts; 17, left ventricular surgery; and 52, both procedures. At 3 years after treatment, unadjusted survival was 84% for surgical patients and 64% for medical patients. At baseline, medical patients had more left ventricular dysfunction than surgical patients, but surgical patients had more coronary artery disease and angina than medical patients. In Cox survival models, two invasive factors (ejection fraction and extent of coronary artery disease) and three noninvasive indexes (assessment of myocardial infarction, angina, and conduction disturbances) were the five best predictors of survival (p less than 0.001). After adjustment for these factors between the two treatment groups, overall surgical survival at 3 years after treatment was 86%, and medical survival was 68%. Long-term surgical survival benefits appeared greatest in patients with the most severe left ventricular dysfunction, most extensive coronary artery disease, and most severe anginal symptoms. We conclude that surgery provides significant survival benefits for coronary disease patients with left ventricular dysfunction; in general, the sicker the patient, the greater the benefit.

Entities:  

Mesh:

Year:  1988        PMID: 3261652

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Assessment of myocardial viability after myocardial infarction.

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  The quest for myocardial viability: Is there a role for nitrate-enhanced imaging?

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

3.  To revascularize or not to revascularize: a dilemma in heart failure.

Authors:  Roxy Senior
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

4.  Revascularize only for ischemia, especially if left ventricular function is poor.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 5.  Imaging techniques in nuclear cardiology for the assessment of myocardial viability.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A J O Dierckx; Pieter L Jager
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

6.  Mid-term results of coronary bypass graft surgery in patients with ischaemic left ventricular systolic dysfunction and no detected myocardial viability.

Authors:  Jun Liu; Zixiong Liu; Anqing Chen; Zhe Wang; Mi Zhou; Junfeng Cai; Qiang Zhao
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-23

Review 7.  Myocardial hibernation in coronary artery disease.

Authors:  Dinesh K Kalra; William A Zoghbi
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

Review 8.  Diagnostic and imaging considerations: role of viability.

Authors:  Roxy Senior
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

9.  Late reopening of an occluded infarct related artery improves left ventricular function and long term clinical outcome.

Authors:  F Piscione; G Galasso; G De Luca; G Marrazzo; G Sarno; O Viola; D Accardo; M Chiariello
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

Review 10.  Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.

Authors:  F A Mitropoulos; J A Elefteriades
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.